+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostics (SPECT, PET), Therapeutics (Alpha Emitters, Beta Emitters, Brachytherapy)), by Application, by Region, and Segment Forecasts, 2020 - 2027

  • ID: 4621710
  • Report
  • February 2020
  • Region: Global
  • 80 pages
  • Grand View Research
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Bracco Imaging S.p.A
  • Curium Pharma
  • Eckert & Ziegler
  • Eczacibasi-Monrol
  • GE Healthcare
  • Jubilant Pharma. LLC
  • MORE
The global nuclear medicine market size is expected to reach USD 12.6 billion by 2027, expanding at a CAGR of 9.5%. Research and development of advanced technologies by the key players for diagnosis and treatment of diseases is expected to drive the radiopharmaceuticals market.

For instance, in May 2019, GE Healthcare with Indi Molecular, Inc., collaborated to develop Protein Catalyzed Capture (PCC) technology and immune cell-targeted PET tracer candidates. This diagnostic tool will help in better understanding of patient’s immune cell and in early treatment response.

Rising prevalence of cancer and cardiovascular diseases is one of the major factors responsible for market growth. Moreover, high prevalence of cancer in emerging Asian countries is creating huge demand for radiopharmaceuticals in diagnosing the disease. For instance, according to the GLOBOCAN, in 2018, approximately 48.4% of cancer cases were registered in Asia.

In addition, presence of standard guidelines prepared by regulatory authorities for radiopharmaceuticals is expected to accelerate market growth. For instance, in August 2019, FDA published a guideline for non-clinical studies and product labelling that are not covered by FDA and ICH guidelines for radiopharmaceuticals used in the treatment of cancer.

Manufacturers are focusing on development of innovative technologies to produce medical isotopes that can fulfill the increasing demand for nuclear medicines. For instance, in October 2018, with the support of ASML, The Institute For Radioelements (IRE) developed and built an electron beamline to manufacture medical isotope molybdenum 99 (Mo-99). Due to this innovative technology, the process of production is waste-free and non-fission.

In addition, research centers and hospitals are launching novel nuclear medicine techniques to treat various diseases at an affordable cost as compared to the existing treatments. For instance, in August 2017, the Kovai Medical Centre and Hospital (KMCH) had launched Rhenium 188 Lipiodol to treat liver cancer and other diseases such as metastatic bone pain, rheumatoid arthritis, and hemophilic bleeding joints at low cost with lesser hospitalization.

Further key findings from the study suggest:
  • In 2019, the SPECT segment had dominated the market owing to integration of SPECT with X-ray/CT that has gained more acceptance and proved to be useful in many clinical situations due to its high accuracy
  • PET diagnostic nuclear medicine is expected to witness the fastest growth over the forecast period owing to the increasing adoption of high resolution PET scanners
  • In case of the therapeutic segment, brachytherapy is anticipated to be the fastest growing segment due to the higher radiation protection as compared to other treatment options
  • The oncology application segment dominated the nuclear medicine market in 2019 owing to the presence of pipeline drugs and high prevalence of cancer
  • The market in Asia Pacific is projected to witness the fastest growth during the forecast period owing to the high unmet needs and development of radiopharmaceuticals for diagnosis and treatment of various diseases
  • Key players in the market include companies such as Eckert and Ziegler Group Nordion, Inc., Bracco Imaging S.p.A., and GE Healthcare as well as government organizations such as Department of Atomic Energy and Australian Nuclear Science and Technology Organization (ANSTO).

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bracco Imaging S.p.A
  • Curium Pharma
  • Eckert & Ziegler
  • Eczacibasi-Monrol
  • GE Healthcare
  • Jubilant Pharma. LLC
  • MORE
Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Scope and Assumptions
1.3 List of Abbreviations

Chapter 2 Executive Summary
2.1 Market Summary

Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation

Chapter 4 Market Definitions

Chapter 5 Industry Outlook
5.1 Market variable Analysis
5.1.1 Rising incidence of cancer and cardiovascular diseases
5.1.2 Increasing application of radiopharmaceuticals
5.1.3 Growing demand for accurate diagnostic methods
5.1.4 Market Restraint Analysis
5.1.4.1 Stringent regulations pertaining to production, storage, & usage
5.1.4.2 High costs associated with diagnostics & therapeutic procedures

Chapter 6 Business Environment Analysis
6.1.1 SWOT Analysis; By factor (POLITICAL & Legal, economic and technological)
6.1.2 Porter’s five forces analysis
6.1.3 Value chain analysis

Chapter 7 Regulatory and Political Forces
7.1 Regulatory Landscape
7.1.1 List of factors/ regulations by country
7.1.1.1 North America
7.1.1.1.1 U.S.
7.1.1.1.2 Canada
7.1.1.2 Europe
7.1.1.2.1 Germany
7.1.1.2.2 U.K.
7.1.1.2.3 France
7.1.1.2.4 Italy
7.1.1.2.5 Spain
7.1.1.2.6 Russia
7.1.1.2.7 Netherlands
7.1.1.3 Asia Pacific
7.1.1.3.1 China
7.1.1.3.2 Japan
7.1.1.3.3 India
7.1.1.3.4 Australia
7.1.1.3.5 New Zealand
7.1.1.3.6 South Korea
7.1.1.3.7 Singapore
7.1.1.3.8 Malaysia
7.1.1.3.9 Philippines
7.1.1.4 Latin America
7.1.1.4.1 Brazil
7.1.1.4.2 Mexico
7.1.1.4.3 Argentina
7.1.1.5 Middle East & Africa
7.1.1.5.1 South Africa
7.1.1.5.2 GCC
7.2 Production Process And Trends
7.2.1 Production of molybdenum-99 (SPECT radioisotopes)
7.2.1.1 SPECT radioisotopes trends
7.2.1.2 PET radioisotopes Trends
7.2.1.3 Therapeutic radioisotopes trends
7.2.1.4 Latest Developments

Chapter 8 Competitive Analysis
8.1 Vendor Landscape
8.1.1 List of key distributors and channel partners
8.1.2 Key company market share analysis, 2019
8.2 Public Companies
8.2.1 Company market position analysis
8.2.2 Competitive Dashboard Analysis
8.3 Private Companies
8.3.1 List of key emerging companies /technology disruptors/innovators
8.3.2 Regional network map

Chapter 9 Product Business Analysis
9.1 Radiopharmaceuticals/Nuclear Medicine Market: Product Movement Analysis
9.2 Diagnostic Products
9.2.1 Diagnostic products market, 2016 - 2027 (USD Million)
9.2.1.1 SPECT
9.2.1.1.1 SPECT products market, 2016 - 2027 (USD Million)
9.2.1.1.2 TC-99m
9.2.1.1.3 TC-99m market, 2016 - 2027 (USD Million)
9.2.1.1.4 TL-201
9.2.1.1.5 TL-201 market, 2016 - 2027 (USD Million)
9.2.1.1.6 GA-67
9.2.1.1.7 GA-67 market, 2016 - 2027 (USD Million)
9.2.1.1.8 I-123
9.2.1.1.9 I-123 market, 2016 - 2027 (USD Million)
9.2.1.1.10 Other SPECT products
9.2.1.1.11 Other SPECT products market, 2016 - 2027 (USD Million)
9.2.1.2 PET
9.2.1.2.1 PET products market, 2016 - 2027(USD Million)
9.2.1.2.2 F-18
9.2.1.2.3 F-18 market, 2016 - 2027 (USD Million)
9.2.1.2.4 SR-82/RB-82
9.2.1.2.5 SR-82/RB-82 market, 2016 - 2027 (USD Million)
9.2.1.2.6 Other PET products
9.2.1.2.7 Other PET products market, 2016 - 2027 (USD Million)
9.3 Therapeutic Products
9.3.1 Therapeutic products market, 2016 - 2027 (USD Million)
9.3.2 Alpha emitters
9.3.2.1 Alpha emitters market, 2016 - 2027 (USD Million)
9.3.2.1.1 RA-223
9.3.2.1.1.1 RA-223 market, 2016 - 2027 (USD Million)
9.3.2.1.2 Other alpha emitters
9.3.2.1.3 Other alpha emitters market, 2016 - 2027 (USD Million)
9.3.3 Beta emitters
9.3.3.1 Beta emitters market, 2016 - 2027 (USD Million)
9.3.3.2 I-131
9.3.3.2.1 I-131 market, 2016 - 2027 (USD Million)
9.3.3.3 Y-90
9.3.3.3.1 Y-90 market, 2016 - 2027 (USD Million)
9.3.3.4 SM-153
9.3.3.4.1 SM-153 market, 2016 - 2027 (USD Million)
9.3.3.5 Re-186
9.3.3.5.1 Re-186 market, 2016 - 2027 (USD Million)
9.3.3.6 Lu-117
9.3.3.6.1 Lu-177 market, 2016 - 2027 (USD Million)
9.3.3.7 Other beta emitters
9.3.3.7.1 Other beta emitters market, 2016 - 2027 (USD Million)
9.3.4 Brachytherapy
9.3.4.1 Brachytherapy market, 2016 - 2027 (USD Million)
9.3.4.2 Cesium-131
9.3.4.2.1 Cesium-131 market, 2016 - 2027 (USD Million)
9.3.4.3 Iodine-125
9.3.4.3.1 Iodine-125 market, 2016 - 2027 (USD Million)
9.3.4.4 Palladium-103
9.3.4.4.1 Palladium-103 market, 2016 - 2027 (USD Million)
9.3.4.5 Iridium-192
9.3.4.5.1 Iridium-192 market, 2016 - 2027 (USD Million)
9.3.4.6 Other brachytherapy products
9.3.4.6.1 Other brachytherapy products market, 2016 - 2027 (USD Million)

Chapter 10 Application Mode Business Analysis
10.1 Radiopharmaceuticals/Nuclear Medicine Market: Application Movement Analysis
10.1.1 Cardiology
10.1.1.1 Cardiology applications market, 2016 - 2027 (USD Million)
10.1.2 Neurology
10.1.2.1 Neurology applications market, 2016 - 2027 (USD Million)
10.1.3 Oncology
10.1.3.1 Oncology applications market, 2016 - 2027 (USD Million)
10.1.4 Thyroid
10.1.4.1 Thyroid applications market, 2016 - 2027 (USD Million)
10.1.5 Lymphoma
10.1.5.1 Lymphoma applications market, 2016 - 2027 (USD Million)
10.1.6 Bone metastasis
10.1.6.1 Bone metastasis applications market, 2016 - 2027 (USD Million)
10.1.7 Endocrine tumor
10.1.7.1 Endocrine tumor market, 2016 - 2027 (USD Million)
10.1.8 Other application
10.1.8.1 Other applications market, 2016 - 2027 (USD Million)

Chapter 11 Regional Business Analysis
11.1 Radiopharmaceuticals/Nuclear Medicine Market: Regional Movement Analysis
11.2 North America
11.2.1 North America Market Estimates And Forecast, 2016 - 2027
11.2.2 U.S.
11.2.2.1 U.S. Market Estimates And Forecast, 2016 - 2027
11.2.3 Canada
11.2.3.1 Canada Market Estimates And Forecast, 2016 - 2027
11.3 Europe
11.3.1 Europe Market Estimates And Forecast, 2016 - 2027
11.3.2 Germany
11.3.2.1 Germany Market Estimates And Forecast, 2016 - 2027
11.3.3 U.K.
11.3.3.1 U.K. Market Estimates And Forecast, 2016 - 2027
11.3.4 France
11.3.4.1 France Market Estimates And Forecast, 2016 - 2027
11.3.5 Italy
11.3.5.1 Italy Market Estimates And Forecast, 2016 - 2027
11.3.6 Spain
11.3.6.1 Spain Market Estimates And Forecast, 2016 - 2027
11.3.7 Russia
11.3.7.1 Russia Market Estimates And Forecast, 2016 - 2027
11.3.8 Netherlands
11.3.8.1 Netherlands Market Estimates And Forecast, 2016 - 2027
11.4 Asia Pacific
11.4.1 Asia Pacific Market Estimates And Forecast, 2016 - 2027
11.4.2 Japan
11.4.2.1 Japan Market Estimates And Forecast, 2016 - 2027
11.4.3 China
11.4.3.1 China Market Estimates And Forecast, 2016 - 2027
11.4.4 India
11.4.4.1 India Market Estimates And Forecast, 2016 - 2027
11.4.5 Australia
11.4.5.1 Australia Market Estimates And Forecast, 2016 - 2027
11.4.6 Singapore
11.4.6.1 Singapore Market Estimates And Forecast, 2016 - 2027
11.4.7 Malaysia
11.4.7.1 Malaysia Market Estimates And Forecast, 2016 - 2027
11.4.8 New Zealand
11.4.8.1 New Zealand Market Estimates And Forecast, 2016 - 2027
11.4.9 South Korea
11.4.9.1 South Korea Market Estimates And Forecast, 2016 - 2027
11.4.10 Philippines
11.4.10.1 Philippines Market Estimates And Forecast, 2016 - 2027
11.5 Latin America
11.5.1 Latin America Market Estimates And Forecast, 2016 - 2027
11.5.2 Brazil
11.5.2.1 Brazil Market Estimates And Forecast, 2016 - 2027
11.5.3 Mexico
11.5.3.1 Mexico Market Estimates And Forecast, 2016 - 2027
11.5.4 Argentina
11.5.4.1 Argentina Market Estimates And Forecast, 2016 - 2027
11.6 Middle East & Africa
11.6.1 Middle-East And Africa Market Estimates And Forecast, 2016 - 2027
11.6.2 Saudi Arabia
11.6.2.1 Saudi Arabia Market Estimates And Forecast, 2016 - 2027
11.6.3 South Africa
11.6.3.1 South Africa Market Estimates And Forecast, 2016 - 2027
11.6.4 Israel
11.6.4.1 Israel Market Estimates And Forecast, 2016 - 2027
11.6.5 Turkey
11.6.5.1 Turkey Market Estimates And Forecast, 2016 - 2027

Chapter 12 Company Profile
12.1 Eckert & Ziegler
12.1.1.1 Company overview
12.1.1.2 Financial performance
12.1.1.3 Product benchmarking
12.1.1.4 Strategic initiatives
12.2 Mallinckrodt
12.1.2.1 Company overview
12.1.2.2 Financial performance
12.1.2.3 Product benchmarking
12.1.2.4 Strategic initiatives
12.3 Curium Pharma
12.1.3.1 Company overview
12.1.3.2 Product benchmarking
12.1.3.3 Strategic initiatives
12.4 GE Healthcare
12.1.4.1 Company overview
12.1.4.2 Financial performance
12.1.4.3 Product benchmarking
12.1.4.4 Strategic initiatives
12.5 Jubilant Pharma. LLC
12.1.5.1 Company overview
12.1.5.2 Financial performance
12.1.5.3 Product benchmarking
12.1.5.4 Strategic initiatives
12.6 Bracco Imaging S.p.A
12.1.6.1 Company overview
12.1.6.2 Product benchmarking
12.1.6.3 Strategic initiatives
12.7 Nordion (Canada) Inc.
12.1.7.1 Company overview
12.1.7.2 Financial performance
12.1.7.3 Product benchmarking
12.1.7.4 Strategic initiatives
12.8 The Institute for Radioelements (IRE - IRE ELiT)
12.1.8.1 Company overview
12.1.8.2 Financial performance
12.1.8.3 Product benchmarking
12.1.8.4 Strategic initiatives
12.9 Australian Nuclear Science & Technology Organization (ANSTO)
12.1.9.1 Company overview
12.1.9.2 Financial performance
12.1.9.3 Product benchmarking
12.1.9.4 STRATEGIC INITIATIVES
12.10 NTP Radioisotopes SOC Ltd.
12.1.10.1 Company overview
12.1.10.2 Financial performance
12.1.10.3 Product benchmarking
12.1.10.4 Strategic initiatives
12.11 Eczacibasi-Monrol
12.1.11.1 Company overview
12.1.11.2 Financial performance
12.1.11.3 Product benchmarking
12.1.11.4 Strategic initiatives
12.12 Lantheus Medical Imaging, Inc.
12.1.12.1 Company overview
12.1.12.2 Financial overview
12.1.12.3 Product benchmarking
12.1.12.4 Strategic initiatives

Full List of Tables and Figures Available on Enquiry.
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Eckert & Ziegler
  • Mallinckrodt
  • Curium Pharma
  • GE Healthcare
  • Jubilant Pharma. LLC
  • Bracco Imaging S.p.A
  • Nordion (Canada) Inc.
  • The Institute for Radioelements (IRE - IRE ELiT)
  • Australian Nuclear Science & Technology Organization (ANSTO)
  • NTP Radioisotopes SOC Ltd.
  • Eczacibasi-Monrol
  • Lantheus Medical Imaging, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll